Article Figures & Data
Figures
- Figure 1
Event-free survival curves for Burkitt lymphoma treated with schedule modified R-CODOX-M/IVAC regimens among total patients (A) and in the low risk and high risk groups (B).
- Figure 2
Progress free survival curves for Burkitt lymphoma patients treated with schedule modified R-CODOX-M/IVAC regimens among total patients (A) and in low risk and high risk groups (B).
- Figure 3
Overall survival curves for Burkitt lymphoma patients treated with schedule modified R-CODOX-M/IVAC regimens among total patients (A) and among low risk and high risk groups (B).
Tables
Characteristics n (%) Male 80 (65.0%) Age (years) Median (range) 36 (18~69) Ann Arbor stage at diagnosis I 33 (26.8%) II 30 (24.4%) III 6 (4.9%) IV 54 (43.9%) IPI score 0~1 61 (49.6%) 2~3 51 (41.5%) 4~5 11 (8.9%) B symptoms Present 25 (20.3%) Absent 98 (79.7%) Serum LDH>ULN 50 (40.7%) Extra-nodal site Bowel 32 (26.0%) Stomach 22 (17.9%) Bone marrow 11 (8.9%) Central nervous system 2 (1.6%) Risk stratification Low 49 (39.8%) High 74 (60.2%) ULN, upper limit of normal; IPI, international prognosis index; LDH, lactate dehydrogenase.
Outcome Low risk, n (%) High risk, n (%) P Best overall response, n (%) Complete remission 46 (93.9%) 60 (81.1%) 0.044* Partial remission 2 (4.1%) 6 (8.1%) / Stable disease 0 (0) 0 (0) Progressed disease 1 (2.0%) 8 (10.8%) Objective response rate 98.0% 89.2% 0.140 Cycles Median (range) 6 (4~8) 6 (4~8) / Therapy duration (months) Median 3.8 4.3 / Range 1.6~6.5 2.2~9.4 Follow-up (months) Median 44.3 39.8 / 95% CI 30.1~58.5 30.1~49.5 *P < 0.05 was considered statistically significant.
Events, n (%) Low risk (n = 49) High risk (n = 74) Total (n = 123) Any grade Grade 3~4 Any grade Grade 3~4 Any grade Grade 3~4 Any adverse event 49 (100%) 46 (93.8%) 74 (100%) 70 (94.6%) 123 (100%) 116 (94.3%) Hematological toxic effects Anemia 47 (95.9%) 21 (42.9%) 73 (98.6%) 51 (68.9%) 120 (97.6%) 72 (58.5%) Leukopenia 47 (95.9%) 43 (87.8%) 74 (100%) 70 (94.6%) 121 (98.4%) 113 (91.9%) Thrombocytopenia 38 (77.5%) 30 (61.2%) 65 (87.8%) 60 (81.1%) 103 (83.7%) 90 (73.2%) Febrile neutropenia 19 (38.8%) 19 (38.8%) 41 (55.4%) 41 (55.4%) 60 (48.8%) 60 (48.8%) Non-hematological toxic effects Fatigue 22 (44.9%) 0 43 (58.1%) 0 65 (52.8%) 0 Diarrhea 5 (10.2%) 0 6 (8.1%) 1 (1.4%) 11 (8.9%) 1 (0.8%) Dyspepsia 22 (44.9%) 0 45 (60.8%) 0 67 (54.5%) 0 Nausea 6 (12.2%) 0 21 (28.4%) 1 (1.4%) 27 (22.0%) 1 (0.8%) Emesis 4 (8.2%) 0 13 (17.6%) 1 (1.4%) 17 (13.8%) 1 (0.8%) Stomatitis 8 (16.3%) 1 (2%) 9 (12.2%) 1 (1.4%) 17 (13.8%) 2 (1.6%) Elevated transaminases 27 (55.1%) 1 (2%) 32 (43.2%) 1 (1.4%) 59 (48.0%) 2 (1.6%) Elevated serum bilirubin 2 (4.1%) 0 9 (12.2%) 0 11 (8.9%) 0 Serum creatinine increased 1 (2%) 0 4 (5.4%) 0 5 (4.1%) 0 Characteristics n (%) Age >60 years 1 (9.1%) LDH >250 U/L 8 (72.7%) IPI ≥ 3 7 (63.6%) Bone marrow involvement 4 (36.4%) Bowel involvement 5 (45.5%) EBER Negative 4 (36.4%) Unavailable data 7 (63.6%) Dose reduction during chemotherapy 2 (18.2%) Best tumor response in first line CODOX-M therapy Complete remission 5 (45.5%) Progressed disease 6 (55.5%) Cause of death Treatment related death 2 (18.2%) Died for progressed disease 9 (81.8%) LDH, lactate dehydrogenase; IPI, international prognosis index; EBER, Epstein-Barr virus-encoded small nuclear early region; CODOX-M, cyclophosphamide, vincristine, doxorubicin, methotrexate.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.